Drug Combo Proves Powerful Against Lung Cancer Ossining NY

A two-drug combination treatment in Ossining proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

RADHA RAGHUPATHY, MD
(781) 254-4499
804 Rockland Avenue
Larchmont, NY
KIRAN YALAMANCHILI, MD
(914) 493-8375
19 Bradhurst Avenue
Hawthorne, NY
Karen Patricia Seiter, MD
914-493-8374
Rm 250 Munger Pavilion
Valhalla, NY
Daniel Omar Izon, MD
Spring Valley, NY
Ephraim Resnik, MD
914-593-8950
Valhalla, NY
Indira Dasgupta
(914) 493-7997
600 E 233rd St
Bronx, NY
JONATHAN GOLDBERG, MD
(914) 241-1050
90 South Bedford Raod
Mount Kisco, NY
Gene David Resnick, MD
914-694-4949
3020 Westchester Ave Ste 202
Purchase, NY
Allen Chinitz, MD
201-634-5600
1 Valley Health Plz
Paramus, NJ
Farooq Ghani, MD
914-524-2149
511 Benedict Ave
Tarrytown, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Ossining NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Delayed Prostate Cancer Therapy Ossining NY
- Hormone Therapy for Lung Cancer Ossining NY
- Hormone Therapy for Breast Cancer Ossining NY
- Genetic Clues for Skin Cancer Therapies Ossining NY
- Exercise for Breast Cancer Survival Ossining NY
- Exercise for Prostate Cancer Ossining NY
- Fungal Infection Treatments Ossining NY
- Risks for Childhood Cancer Survivors Ossining NY